The Africa Centres for Disease Control and Prevention (Africa CDC) has initiated patient enrollment for the 'MpOx Study in Africa' (MOSA) at Mbandaka Hospital in the Democratic Republic of Congo. This pan-African randomized platform adaptive trial will evaluate the safety and efficacy of brincidofovir, an antiviral from Emergent BioSolutions, for treating mpox virus.
Brincidofovir is currently available for mpox in the U.S. under an emergency Investigational New Drug protocol, but its safety and efficacy for mpox have not yet been established in double-blind, placebo-controlled studies. The MOSA trial aims to provide critical data on this potential treatment option, with a first interim analysis expected by the end of Q1 2025.
Mpox remains a significant health threat across Africa, particularly for vulnerable populations, and there is currently no approved therapeutic to treat the virus in the United States or Africa. This study represents a groundbreaking step in African-led research to address this urgent healthcare gap.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.